)
“Used in the treatment of peptic ulcers, gastritis and gastroesophageal reflux disease (GERD), ranitidine Hcl falls in the anti-secretory segment. The company has received USFDA approval to market ranitidine Hcl injections 25 mg /ml,” the company informed in a statement issued today.
“The estimated sales in 2012 as per IMS for ranitidine Hcl injection had been around $5.4 million (approx. Rs 29.14 crore).
The group now has 76 approvals and has so far filed 172 ANDAs since the commencement of the filing process in FY 2003-04, the company stated.
Cadila Healthcare shares closed at Rs 774.95 on Bombay Stock Exchange (BSE) with marginal loss of 0.08 per cent from previous close.
